The AI That Sees Cancer Five Years Early

The algorithm is called Mirai. Developed by researchers at MIT's Computer Science and Artificial Intelligence Laboratory, it was trained on over 200,000 mammograms from Massachusetts General Hospital. Unlike traditional risk models that rely on family history, age, and genetics, Mirai works directly from the image itself. It reads patterns in breast tissue that are invisible to the human eye.

A landmark study across the NHS England Breast Screening Programme examined 175,000 women. The results were striking. Mirai identified 25% of so-called "interval cancers," the ones that appear between routine screenings and are typically caught late. These are the cancers that slip through the cracks of standard screening programmes. The AI flagged them years before they became clinically apparent.

Breast cancer screening is just the beginning. AI diagnostic tools are expanding across medical imaging at pace.

Brain MRIs in seconds. Researchers at the University of Michigan built a system that interprets brain MRI scans in seconds, a process that typically takes radiologists 20-30 minutes per scan. The system identifies abnormalities across stroke, tumour, and neurodegenerative conditions with accuracy comparable to specialist neuroradiologists.

Biological age from chest X-rays. A team at Osaka Metropolitan University demonstrated that AI can estimate a patient's biological age from a standard chest X-ray, then flag individuals whose biological age significantly exceeds their chronological age. These patients carry higher risk for cardiovascular disease, respiratory illness, and early mortality. The information was always in the image. Nobody could see it until now.

None of this replaces radiologists. That framing misses the point entirely.

The model that works is triage and augmentation. AI scans every image first, flagging cases that warrant closer attention and prioritising the queue by risk level. Radiologists then focus their expertise where it matters most, on complex cases, on ambiguous findings, on the conversations with patients that require human judgement and empathy.

The NHS study found that AI-assisted reading reduced radiologist workload by 44% while maintaining diagnostic accuracy. Fewer missed cancers. Less burnout. Better allocation of specialist time.

This matters because radiologist shortages are real and worsening. The Royal College of Radiologists reported a 30% shortfall in the UK workforce. NZ faces similar pressures. AI doesn't solve the shortage, but it makes the existing workforce dramatically more effective.

Population-level screening is expensive and resource-constrained. Most countries screen women over 50 every two to three years. The intervals exist because the system cannot process more volume with existing staff.

AI changes this calculation. If every mammogram can be risk-scored automatically, screening programmes can move from fixed intervals to risk-adaptive scheduling. High-risk patients get screened more frequently. Low-risk patients get reassurance backed by data, not just averages.

This is health, not just technology. The stakes are different from optimising a supply chain or automating a workflow.

False positives cause anxiety, unnecessary biopsies, and real psychological harm. False negatives cost lives. Every deployment of AI in medical imaging must be validated against diverse populations, monitored for drift, and governed with clinical oversight that prioritises patient welfare above throughput.

The early results are extraordinary. But rolling these systems out responsibly, across different populations, healthcare systems, and regulatory environments, requires the same care as any medical intervention.

The science is moving fast. The governance needs to keep pace.